

**FINANCIAL STATEMENTS (Un-Audited)**  
**For the period from 01.07.2017 to 31.03.2018**



**THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.**  
Tanim Center, 3 Asad Gate, Mirpur Road, Mohammadpur,  
Dhaka-1207, Bangladesh.

# THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207

As per requirement of the Bangladesh Securities & Exchange Commission's (BSEC) Notification No. BSEC/CMRRCD/2009- 193/Admin/69 dated September 07, 2016, The IBN SINA Pharmaceutical Industry Ltd. is pleased to submit the un-audited Financial Statements for the nine months period ended 31st March, 2018.

## STATEMENT OF FINANCIAL POSITION (Un-Audited)

As at 31st March, 2018

Amount in Taka


	Notes	As at 31.03.2018	As at 30.06.2017
<b>ASSETS:</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	02	1,315,263,016	1,116,332,498
Capital work-in-progress	02.1	80,656,316	26,614,186
Investment in Marketable Securities (AFS)	03	304,904,859	359,107,400
Investment	03.01	17,123,147	9,123,147
		<b>1,717,947,338</b>	<b>1,511,177,231</b>
<b>Current Assets :</b>			
Inventories	04	333,773,742	264,194,238
Accounts Receivable		25,145,371	14,642,851
Advances, Deposits & Prepayments	05	246,203,777	167,384,398
Cash & Cash Equivalents	06	186,769,066	197,423,176
		<b>791,891,956</b>	<b>643,644,663</b>
<b>TOTAL ASSETS</b>		<b><u>2,509,839,294</u></b>	<b><u>2,154,821,894</u></b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES:</b>			
<b>Shareholders' Equity:</b>			
Share Capital		284,032,980	258,211,800
Net Gain on Marketable Securities (AFS)	03	240,730,111	289,485,578
Tax Holiday Reserve		4,392,110	4,392,110
Retained Earnings	07	679,883,479	552,873,744
		<b>1,209,038,680</b>	<b>1,104,963,231</b>
<b>Non-Current Liabilities</b>			
Deferred Tax Liability	08	382,968,167	242,737,392
	09.1	69,723,856	80,513,227
		<b>452,692,023</b>	<b>323,250,619</b>
<b>Current Liabilities:</b>			
Bank & Other Finance	10	391,526,971	326,811,195
Accounts and Other Payables	11	456,581,620	399,796,849
		<b>848,108,591</b>	<b>726,608,044</b>
<b>TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES</b>		<b><u>2,509,839,294</u></b>	<b><u>2,154,821,894</u></b>

Net Asset Value (NAV) per Share (restated-2016-2017)

42.57

38.90


  
Chief Financial Officer

  
Company Secretary

  
Director

Dated, Dhaka  
25-Apr-18

  
Managing Director

  
Chairman

**THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.**  
**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME ( Un-Audited )**  
For the period from 1st July 2017 to 31st March, 2018

Amount in Taka				
Notes	July 01, 2017 to March 31, 2018	July 01, 2016 to March 31, 2017	January 01, 2018 to March 31, 2018	January 01, 2017 to March 31, 2017
Revenue	3,497,907,314	2,963,631,376	1,028,127,632	985,045,127
Cost of goods sold	(2,050,121,027)	(1,738,377,794)	(582,521,490)	(560,865,791)
<b>Gross Profit</b>	<b>1,447,786,287</b>	<b>1,225,253,582</b>	<b>445,606,142</b>	<b>424,179,336</b>
<b>Operating Expenses:</b>				
Administrative expenses	(86,854,146)	(74,900,173)	(31,795,224)	(28,533,667)
Selling & Distribution expenses	(1,042,677,122)	(890,779,707)	(336,003,132)	(325,243,535)
	<b>(1,129,531,268)</b>	<b>(965,679,880)</b>	<b>(367,798,356)</b>	<b>(353,777,202)</b>
<b>Operating Profit</b>	<b>318,255,019</b>	<b>259,573,702</b>	<b>77,807,786</b>	<b>70,402,134</b>
Financial charges	(28,816,005)	(15,555,805)	(10,968,011)	(7,631,971)
Other income	629,758	3,082,629	278,960	1,046,577
	<b>290,068,772</b>	<b>247,100,526</b>	<b>67,118,735</b>	<b>63,816,740</b>
Workers' P.P. Fund & Welfare Fund	(13,812,799)	(11,766,692)	(3,196,130)	(3,038,892)
<b>Net Profit before tax</b>	<b>276,255,973</b>	<b>235,333,834</b>	<b>63,922,605</b>	<b>60,777,848</b>
Less: Income tax expenses				
Current tax	(64,244,205)	(50,450,310)	(16,552,731)	(14,350,563)
Deferred tax	5,372,097	(546,961)	907,446	(7,247,030)
	<b>(58,872,109)</b>	<b>(50,997,271)</b>	<b>(15,645,286)</b>	<b>(21,597,593)</b>
<b>Net Profit after tax</b>	<b>217,383,865</b>	<b>184,336,563</b>	<b>48,277,320</b>	<b>39,180,255</b>
Other Comprehensive Income:				
Change in fair value of Marketable Securities (AFS)	(54,172,741)	131,284,518	(102,689,382)	125,694,902
Deferred tax	5,417,274	(13,128,452)	10,268,938	(12,569,490)
Total other comprehensive income, net of tax	<u>(48,755,467)</u>	<u>118,156,066</u>	<u>(92,420,443)</u>	<u>113,125,412</u>
<b>Total other comprehensive income</b>	<b><u>168,628,398</u></b>	<b><u>302,492,629</u></b>	<b><u>(44,143,124)</u></b>	<b><u>152,305,667</u></b>
<b>Earnings per share-basic (restated-2016-2017)</b>	<b><u>7.65</u></b>	<b><u>6.49</u></b>	<b><u>1.70</u></b>	<b><u>1.38</u></b>

  
Chief Financial Officer

  
Company Secretary

  
Director

Dated, Dhaka  
25-Apr-18

  
Managing Director

  
Chairman



**THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.**


**STATEMENT OF CHANGES IN EQUITY (Un-Audited)**

For the period from 1st July 2017 to 31st March, 2018

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
<b>Balance as at 1st July, 2016</b>	<b>224,532,000</b>	<b>4,392,110</b>	<b>259,716,820</b>	<b>380,790,698</b>	<b>869,431,628</b>
Net profit After tax	-	-	29,768,758	233,829,346	263,598,104
Dividend for the year 30 June, 2016 (cash-12.50%)				(28,066,500)	(28,066,500)
Dividend for the year 30 June, 2016 (stock-5%)	33,679,800			(33,679,800)	
<b>Balance as at 1st July, 2017</b>	<b>258,211,800</b>	<b>4,392,110</b>	<b>289,485,578</b>	<b>552,873,744</b>	<b>1,104,963,232</b>
Total Comprehensive Income/(Loss) for the period ended 31st March, 2018			(48,755,467)	217,383,865	168,628,398
Dividend for the year 30 June, 2017 (Cash-25%)				(64,552,950)	(64,552,950)
Dividend for the year 30 June, 2017 (Stock-10%)	25,821,180			(25,821,180)	-
<b>Balance as at 31st March, 2018</b>	<b>284,032,980</b>	<b>4,392,110</b>	<b>240,730,111</b>	<b>679,883,479</b>	<b>1,209,038,680</b>


  
Chief Financial Officer

  
Company Secretary

  
Director

Dated, Dhaka  
25-Apr-18

  
Managing Director

  
Chairman

**THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.**

**STATEMENT OF CASH FLOWS (Un-Audited)**

For the period from 1st July 2017 to 31st March, 2018

Amount in Taka

<b>1st July 2017 to 31st March 2018</b>	<b>1st July 2016 to 31st March 2017</b>
---	---

**Cash Flow From Operating Activities:**

Collection from revenue & others	3,486,775,036	2,952,046,227
Payment for cost & expenses & others	(3,246,184,733)	(2,783,944,961)
Miscellaneous Income	429,111	536,940
<b>Cash generated from operations</b>	<b>241,019,414</b>	<b>168,638,206</b>
Income tax paid	(56,924,187)	(30,455,621)
Financial charges	(28,816,005)	(15,555,805)
<b>Net cash flows from operating activities</b>	<b>155,279,222</b>	<b>122,626,780</b>

**Cash Flow From Investing Activities:**

Purchase of fixed assets	(272,218,695)	(130,572,280)
Investment	(7,970,200)	(4,000,000)
Profit from bank deposits & investment	200,647	1,835,962
<b>Net cash used in investing activities</b>	<b>(279,988,248)</b>	<b>(132,736,318)</b>

**Cash Flow From Financing Activities:**

Payment of dividend	(55,850,839)	(85,303,001)
Long term finance received/(paid) from bank (net)	105,189,980	97,509,151
Short term finance received/(paid) from bank (net)	64,715,775	5,070,750
<b>Net cash flow from financing activities</b>	<b>114,054,916</b>	<b>17,276,900</b>
Increase/(decrease) in cash and cash equivalents	(10,654,110)	7,167,362
Cash and cash equivalents at the opening	197,423,176	169,305,904
<b>Cash and cash equivalents at the closing</b>	<b>186,769,066</b>	<b>176,473,266</b>

**Net operating cash flow per share (NOCFPS)  
(restated-2016-2017)**

5.47

4.32


  
Chief Financial Officer

  
Company Secretary

  
Director

Dated, Dhaka  
25-Apr-18

  
Managing Director

  
Chairman

# The Ibn Sina Pharmaceutical Industry Ltd.

Selected Notes to the Financial Statements (Un-Audited)

For the period ended March 31, 2018

## Selected Explanatory Notes

### 01 (a). Basis of Preparation of Financial Statements

These financial Statements have been prepared in line with the accounting policies and methods of computations of the annual financial statements prepared and published for the year ended 30th June, 2017. These interim financial statements includes only selected explanatory notes as deemed appropriate for understanding of these un-audited financial statements.

### 01 (b). Reporting

This 3rd Quarter financial report has been prepared based on Bangladesh Accounting Standard (BAS)-34 "Interim Financial Reporting".

### 01 (c). Earnings Per Share (EPS)

Earnings per share has been calculated based on number of shares outstanding for the period ended March 31, 2018 and profit for the same period. The number of shares outstanding for the period was 28.403 million. Earnings per share for the corresponding period of 2016-2017 has also been calculated based on 28.403 million shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

### 01. (d) Finance charge:

Long term loan balance was Tk.334,685,927.00 and 229,495,947.00 on 31 March 2018 and 30 June 2017 respectively. Due to increase in long term loan finance charge was increased during the reporting period.

### 01 (e). Subsequent events

No Material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

Previous period figures have been re-arranged to conform to current period's presentation, where considered necessary.

## 02. PROPERTY, PLANT AND EQUIPMENT:

### Cost/Revaluation

Opening Balance

Addition during the period

Disposal/Adjustment during the period

### Accumulated Depreciation

Opening Balance

Charged during the period

Disposal/Adjustment during the period

### Written Down Value (WDV)

### 02.1 Capital work-in-progress

Construction work-in-progress (Building)

Machinery in transit

## 03. INVESTMENT IN MARKETABLE SECURITIES (FAIR VALUE):

Amount in Taka	
As at 31.03.2018	As at 30.06.2017

1,606,348,997	1,352,403,379
272,218,695	257,621,978
-	(3,676,360)
<b>1,878,567,692</b>	<b>1,606,348,996</b>

490,016,498	400,679,809
73,288,178	92,504,197
-	(3,167,508)
<b>563,304,676</b>	<b>490,016,498</b>
<b>1,315,263,016</b>	<b>1,116,332,498</b>

37,725,200	26,614,186
42,931,116	-
<b>80,656,316</b>	<b>26,614,186</b>

SI No.	Name of Company Share/Bond	No. of Shares /Bond Held	Face Value Per Share /Bond	Cost of Holding	Average Cost	Quoted Rate Per Share/ Bond as on 31.03.18	Total Market value of shares/ Bond as on 31.03.18	Unrealized Gain/(Loss)
1	Islami Bank Bangladesh Ltd. (IBBL)- in shares	11,003,991	10	32,836,958	2.98	27.30	300,408,954	267,571,996
2	Islami Bank Bangladesh Ltd. (IBBL)-in Mudaraba Perpetual Bond (MPB)	4,590	1,000	4,590,000	1,000	979.50	4,495,905	(94,095)
	<b>Total Taka</b>			<b>37,426,958</b>			<b>304,904,859</b>	<b>267,477,901</b>



		Amount in Taka	
		As at 31.03.2018	As at 30.06.2017
a)	<b>NET GAIN/(LOSS) ON MARKETABLE SECURITIES (AFS) :</b>		
	Unrealized Gain/(Loss) Position (Closing)	267,477,901	321,650,642
	Deferred tax on gain on marketable securities (AFS)	(26,747,790)	(32,165,064)
		<b>240,730,111</b>	<b>289,485,578</b>
b)	<b>CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES (AFS) :</b>		
	Unrealized Gain/(Loss) Position (Closing)	267,477,901	321,650,642
	Unrealized Gain/(Loss) Position (Opening)	(321,650,642)	(288,574,244)
		<b>(54,172,741)</b>	<b>33,076,398</b>
<b>03.1</b>	<b>INVESTMENT IN ASSOCIATE</b>		
	Opening balance	9,123,147	1,750,000
	Add: Addition during the year	8,000,000	8,000,000
	Less: Share of associate profit/(loss)	-	(626,853)
	IBN SINA Consumer Products Ltd.	<b>17,123,147</b>	<b>9,123,147</b>
	IBN SINA Consumer Products Ltd. (40% of total share holding)		
<b>04.</b>	<b>INVENTORIES:</b>		
	Raw materials	117,104,697	88,563,456
	Packing materials	93,740,604	68,253,484
	Work-in-process	48,793,692	43,928,563
	Finished goods	72,410,530	61,978,640
	Physicians' samples & others	1,724,219	1,470,095
		<b>333,773,742</b>	<b>264,194,238</b>
<b>05.</b>	<b>ADVANCES, DEPOSITS &amp; PRE-PAYMENTS :</b>		
	<i>This is recoverable in cash or for value to be received and consists of as follows :</i>		
	<b>a. Advances against-</b>		
	Salary	2,829,403	2,104,138
	Expenses/Works	7,260,776	4,964,944
	Head office	9,861,000	7,965,000
	Sales centre rent	9,092,625	9,036,110
	Motor cycles - To employees	7,991,985	5,649,951
	Income Tax	184,964,053	123,113,838
	Others	353,100	247,492
		222,352,942	153,081,473
	<b>b. Deposits -</b>		
	Security money	13,025,983	12,727,278
	<b>c. Pre-payments -</b>		
	Value Added Tax (VAT)	10,583,721	1,009,106
	Insurance premium	241,131	566,541
		10,824,852	1,575,647
	<b>(a+b+c)</b>	<b>246,203,777</b>	<b>167,384,398.00</b>
<b>06.</b>	<b>CASH &amp; CASH EQUIVALENTS:</b>		
	Cash in hand & Bank Balance	180,432,666	191,833,176
	Imprest Cash	6,336,400	5,590,000
		<b>186,769,066</b>	<b>197,423,176</b>
<b>07.</b>	<b>RETAINED EARNINGS :</b>		
	Retained Earnings	552,873,744	380,790,698
	Dividend Paid	(90,374,130)	(61,746,300)
	Add : Surplus during the period/year	217,383,865	233,829,346
		<b>679,883,479</b>	<b>552,873,744</b>

Amount in Taka	
As at 31.03.2018	As at 30.06.2017

**08. NON-CURRENT LIABILITIES:**

Long Term Finance-Net off current maturity  
Retirement Benefit Obligation

334,685,927	229,495,947
48,282,241	13,241,445
<b>382,968,168</b>	<b>242,737,392</b>

09. Deferred tax has been calculated based on deductible/ taxable temporary difference arising due to difference in the carrying amount of the assets and its tax base in accordance with the provision of Bangladesh Accounting Standard (BAS)-12 "Income Taxes":

**Increase/(Decrease) in Deferred tax liabilities:**

Opening deferred tax liability	(48,348,163)	(39,478,199)
Closing deferred tax liability	(42,976,066)	(48,348,163)
<b>Deferred tax (benefit)/expense</b>	<b>(5,372,097)</b>	<b>8,869,964</b>

Particulars	Carrying amount on reporting date	Tax base	(Deductible)/ Taxable temporary difference	Tax Rate @ 25%
<b>At 31 March 2018</b>				
Property, plant and equipment	1,315,263,016	1,108,514,271	206,748,745	(51,687,186)
Gratuity provision	54,123,632	19,279,152	(34,844,480)	8,711,120
<b>Deferred tax liability</b>				<b>(42,976,066)</b>

Particulars	Carrying amount on reporting date	Tax base	(Deductible)/ Taxable temporary	Tax Rate @ 25%
<b>At 30 June 2017</b>				
Property, plant and equipment	1,116,332,498	903,857,010	212,475,488	(53,118,872)
Gratuity provision	71,100,512	52,017,676	(19,082,836)	4,770,709
<b>Deferred tax liability</b>				<b>(48,348,163)</b>

**09.1. DEFERRED TAX ASSET/LIABILITY :**

Deferred Tax Asset/Liability represents deferred tax recognized as asset/liability the movement of which is as below:

**a) Deferred tax liability on net temporary differences:**

Balance as at 1st January	48,348,164	39,478,199
Deferred tax expenses/(income)	(5,372,097)	8,869,965
	<b>42,976,067</b>	<b>48,348,164</b>

**b) Deferred tax liability on change in AFS :**

Balance as at 1st January	32,165,063	28,857,423
Addition/(Less) during the year	(5,417,274)	3,307,640
	<b>26,747,789</b>	<b>32,165,063</b>
<b>Deferred tax liability at closing balance (a+b)</b>	<b>69,723,856</b>	<b>80,513,227</b>

**10. BANK & OTHER FINANCE :**

Short Term Finance  
Long Term Finance-Current maturity

356,734,889	280,421,753
34,792,082	46,389,442
<b>391,526,971</b>	<b>326,811,195</b>

**11. ACCOUNTS AND OTHER PAYABLES:**

Payable for Suppliers  
Accrued Expenses  
Deposits  
Other Finance  
Income Tax Liability

119,988,625	141,010,095
81,080,866	85,580,582
7,731,759	7,183,446
64,454,954	51,867,542
183,325,417	114,155,184
<b>456,581,621</b>	<b>399,796,849</b>



**12. COST OF GOODS SOLD :**

Materials  
 Factory Overhead  
 Depreciation

Amount in Taka	
1st July 2017 to 31st March 2018	1st July 2016 to 31st March 2017
1,629,775,843	1,367,975,843
357,832,013	316,597,338
62,513,171	53,804,613
<b>2,050,121,027</b>	<b>1,738,377,794</b>

**13. ADMINISTRATIVE EXPENSES :**

Salary, wages & Allowances  
 Repairs & Maintenance  
 Travelling & Conveyance  
 AGM, Fees and Others  
 Depreciation  
 Other Expenses

50,171,798	40,635,888
5,228,709	4,779,122
2,868,299	2,514,147
2,013,453	1,955,370
4,015,613	3,885,256
22,556,275	21,130,390
<b>86,854,146</b>	<b>74,900,173</b>

**14. SELLING & DISTRIBUTION EXPENSES :**

Salary, wages & Allowances  
 Travelling & Conveyance  
 Market Survey & Research and Product development  
 Field personnel expenses  
 Sample, Literature & Promotional Expenses  
 Delivery Expenses  
 Depreciation  
 Other Expenses

591,445,976	538,804,692
3,318,364	2,494,317
4,028,495	2,831,836
136,448,956	76,493,957
59,544,051	53,585,429
99,897,931	86,366,196
7,159,394	6,965,826
140,833,955	123,237,454
<b>1,042,677,122</b>	<b>890,779,707</b>

  
 Chief Financial Officer

  
 Company Secretary

  
 Director

Dated, Dhaka  
 25-Apr-18

  
 Managing Director

  
 Chairman